GlassScriptPhysician profile
Jason A Merrick
NPI 1578524435
$3,094.12
in general payments reported to CMS, 2019-2025
35 companies · $388 in 2025
The $388 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $186 · 2020: $415 · 2021: $379 · 2022: $624 · 2023: $581 · 2024: $521 · 2025: $388.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,490.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,489.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $536.05 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbott Laboratories | $371.18 | 2021-2025 | Freestyle Libre 3, Cardiomems |
| Corium, LLC | $271.79 | 2022-2024 | Azstarys |
| Amgen INC. | $239.79 | 2019-2024 | Otezla, Repatha |
| Novo Nordisk INC | $224.02 | 2019-2025 | Wegovy |
| Supernus Pharmaceuticals, INC. | $218.11 | 2022-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $154.14 | 2022-2024 | Jornay Pm |
| Eisai INC. | $98.18 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $92.25 | 2020-2022 | |
| Abbvie INC. | $89.54 | 2021-2024 | |
| Lilly USA, LLC | $82.75 | 2024-2025 | Mounjaro, Zepbound |
| Merck Sharp & Dohme LLC | $75.09 | 2019-2024 | Gardasil 9, Gardasil, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.40 | 2020-2024 | |
| Janssen Pharmaceuticals, INC | $55.26 | 2019-2023 | Spravato |
| Astellas Pharma US INC | $50.06 | 2025 | Veozah |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $44.70 | 2022-2025 | Dyanavel Xr |
| Silk Road Medical, INC. | $37.09 | 2024 | Enroute Transcarotid Neuroprotection System, Enroute Enflate Transcarotid Rx Balloon Dilatation Catheter, Enroute Transcarotid Stent |
| Boston Scientific Corporation | $34.31 | 2025 | Wavewriter Alpha Prime 16 |
| Horizon Therapeutics Plc | $33.28 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $32.36 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $29.34 | 2020-2023 | Trulance, Xifaxan |
| Allergan, INC. | $29.33 | 2020 | |
| Mylan Specialty L.P. | $24.41 | 2024 | Yupelri |
| Acadia Pharmaceuticals INC | $23.68 | 2025 | Daybue |
| Bausch Health US, LLC | $22.69 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.97 | 2020 | |
| Antares Pharma, INC. | $20.24 | 2022 | |
| Sunovion Pharmaceuticals INC. | $18.09 | 2020 | |
| Sanofi Pasteur INC. | $17.63 | 2023 | |
| Pfizer INC. | $16.81 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $16.75 | 2023 | Fasenra |
| Nevro Corp. | $15.03 | 2023 | Senza |
| Teva Pharmaceuticals USA, INC. | $13.04 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $12.64 | 2020 | |
| Esperion Therapeutics, INC. | $12.12 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Merrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.